General Internal Medicine

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Assess Bone Quality Characteristics, Comparing Type 2 Diabetes Patients who have or have not had Prior Fragile Bone Fractures

   Rochester, Minn.

   The purpose of this study is to assess key characteristics of bone quality, specifically material strength and porosity, in patients who have type 2 diabetes. These patients are at an unexplained increased risk for fractures and there is an urgent need to refine clinical assessment for this risk.

2. Mindful Breathing Awareness Through Pursed-Lip Breathing Training

   Rochester, Minn.

   To establish the feasibility of a tool that monitors and motivates people with COPD to complete training in mindful pursed-lip breathing to enhance pulmonary rehabilitation at home.

3. Phase II Study of EUS-guided Verteporfin PDT in Solid Pancreatic Tumors

   Rochester, Minn., Jacksonville, Fla.

   The goal of project is to target of locally advanced pancreatic cancer (LAPC) with a photodynamic therapy (PDT) to evaluate response of tumor.

4. Fecal Microbiome Transplant National Registry

   Rochester, Minn.

   The overarching goal of the FMT registry is to expand knowledge and optimize practice in the transplantation of fecal microbiota or other gut-related-microbiota products.

5. Genetic Predictors of QT Prolongation with Anti-arrhythmic Medication

   Rochester, Minn.

   The purpose of this study is to assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in patients being started on dofetilide. We will examine the predictiveness of a QT genotype score on QT prolongation in patients admitted for dofetilide initiation.
    

6. Epidemiology of Diabetes Interventions and Complications (EDIC)

   Rochester, Minn.

   The purpose of this study is to use the well-characterized Diabetes Control and Complications Trial (DCCT) cohort of 1,400 patients to determine the long-term effects of prior separation of glycemic levels on micro- and macrovascular outcomes.

7. A Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics, and Effectiveness of CC-220 in Combination with Other Treatments in Subjects with Relapsed and Refractory Multiple Myeloma

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as monotherapy and in combination with dexamethasone. The study will consist of an escalating dose-escalation portion (Part 1) as well as an expansion of each cohort (ie, Cohort C: Monotherapy (MonoT) and Cohort D: Combination treatment with 2 drugs (DoubleT) at the recommended Phase 2 dose (RP2D) to further evaluate safety and estimate preliminary efficacy (Part 2).

8. Neural Circulatory Control and SUDEP Risk.

   Rochester, Minn.

   The investigators believe epilepsy alters the way the body controls blood pressure, heart rate and breathing, and these changes increase the risk of sudden unexpected death in patients with epilepsy (SUDEP). SUDEP-7 is a risk scoring tool which may correlate with these changes to the heart and blood vessels. This research study measures those differences which may help identify new markers to help predict those patients at greatest risk in the future.

9. A Study to Collect Data and Blood Samples from Mayo Patients Who have or are Suspected to have Amyloidosis, or Their Family Members, for Future Research

   Rochester, Minn.

   The purpose of this study is to create a data collection and bioregistry of blood samples from Mayo Clinic patients with amyloidosis, suspected amyloidosis, and family members of patients with amyloidosis. This information will be available for future research about this spectrum of diseases.

10. Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

    Rochester, Minn.

    This randomized phase II trial studies how well iodine I-131works with or without selumetinib in treating patients with thyroid cancer that has returned or has spread from where it started to other places in the body. Many thyroid cancers absorb iodine. Because of this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer as part of standard practice. It is thought that the more thyroid tumors are able to absorb radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or without selumetinib in treating thyroid cancer.